Vernakalant - A promising therapy for conversion of recent-onset atrial fibrillation

Gerald V. Naccarelli, Deborah L. Wolbrette, Soraya Samii, Javier E. Banchs, Erica Penny-Peterson, Robert Stevenson, Mario D. Gonzalez

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Background: This paper reviews the pharmacology, electrophysiology, efficacy and safety of intravenous and oral vernakalant hydrochloride (RSD-1235), a novel antiarrhythmic drug that has relative atrial selectivity by blocking potassium channels that are present in the atria and not the ventricle. in addition, this drug has important rate-dependent sodium channel blocking properties. Methods: Currently, there few commercially approved intravenous antiarrhythmic agents for the conversion of atrial fibrillation. intravenously, vernakalant has been demonstrated to be useful in terminating over 50% of recent-onset atrial fibrillation (< 7 days duration) with minimal ventricular proarrhythmic effects. Intravenous vernakalant is not effective in terminating atrial flutter. Oral vernakalant is currently undergoing study and appeats to be effective in suppressing atrial fibrillation recurrences after cardioversion of persistent atrial fibrillation. Results/conclusion: Intravenous vernakalant has the potential to be an important agent in the conversion of atrial fibrillation and oral vernakalant may be a useful drug for the suppression of atrial fibrillation recurrences.

Original languageEnglish (US)
Pages (from-to)805-810
Number of pages6
JournalExpert Opinion on Investigational Drugs
Volume17
Issue number5
DOIs
StatePublished - May 1 2008

Fingerprint

Atrial Fibrillation
Therapeutics
Recurrence
Electric Countershock
Atrial Flutter
Sodium Channels
Electrophysiology
Anti-Arrhythmia Agents
Potassium Channels
vernakalant
Pharmaceutical Preparations
Pharmacology
Safety

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{6775171e6ef64fd793b9d2b8826d79c1,
title = "Vernakalant - A promising therapy for conversion of recent-onset atrial fibrillation",
abstract = "Background: This paper reviews the pharmacology, electrophysiology, efficacy and safety of intravenous and oral vernakalant hydrochloride (RSD-1235), a novel antiarrhythmic drug that has relative atrial selectivity by blocking potassium channels that are present in the atria and not the ventricle. in addition, this drug has important rate-dependent sodium channel blocking properties. Methods: Currently, there few commercially approved intravenous antiarrhythmic agents for the conversion of atrial fibrillation. intravenously, vernakalant has been demonstrated to be useful in terminating over 50{\%} of recent-onset atrial fibrillation (< 7 days duration) with minimal ventricular proarrhythmic effects. Intravenous vernakalant is not effective in terminating atrial flutter. Oral vernakalant is currently undergoing study and appeats to be effective in suppressing atrial fibrillation recurrences after cardioversion of persistent atrial fibrillation. Results/conclusion: Intravenous vernakalant has the potential to be an important agent in the conversion of atrial fibrillation and oral vernakalant may be a useful drug for the suppression of atrial fibrillation recurrences.",
author = "Naccarelli, {Gerald V.} and Wolbrette, {Deborah L.} and Soraya Samii and Banchs, {Javier E.} and Erica Penny-Peterson and Robert Stevenson and Gonzalez, {Mario D.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1517/13543784.17.5.805",
language = "English (US)",
volume = "17",
pages = "805--810",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

Vernakalant - A promising therapy for conversion of recent-onset atrial fibrillation. / Naccarelli, Gerald V.; Wolbrette, Deborah L.; Samii, Soraya; Banchs, Javier E.; Penny-Peterson, Erica; Stevenson, Robert; Gonzalez, Mario D.

In: Expert Opinion on Investigational Drugs, Vol. 17, No. 5, 01.05.2008, p. 805-810.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Vernakalant - A promising therapy for conversion of recent-onset atrial fibrillation

AU - Naccarelli, Gerald V.

AU - Wolbrette, Deborah L.

AU - Samii, Soraya

AU - Banchs, Javier E.

AU - Penny-Peterson, Erica

AU - Stevenson, Robert

AU - Gonzalez, Mario D.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Background: This paper reviews the pharmacology, electrophysiology, efficacy and safety of intravenous and oral vernakalant hydrochloride (RSD-1235), a novel antiarrhythmic drug that has relative atrial selectivity by blocking potassium channels that are present in the atria and not the ventricle. in addition, this drug has important rate-dependent sodium channel blocking properties. Methods: Currently, there few commercially approved intravenous antiarrhythmic agents for the conversion of atrial fibrillation. intravenously, vernakalant has been demonstrated to be useful in terminating over 50% of recent-onset atrial fibrillation (< 7 days duration) with minimal ventricular proarrhythmic effects. Intravenous vernakalant is not effective in terminating atrial flutter. Oral vernakalant is currently undergoing study and appeats to be effective in suppressing atrial fibrillation recurrences after cardioversion of persistent atrial fibrillation. Results/conclusion: Intravenous vernakalant has the potential to be an important agent in the conversion of atrial fibrillation and oral vernakalant may be a useful drug for the suppression of atrial fibrillation recurrences.

AB - Background: This paper reviews the pharmacology, electrophysiology, efficacy and safety of intravenous and oral vernakalant hydrochloride (RSD-1235), a novel antiarrhythmic drug that has relative atrial selectivity by blocking potassium channels that are present in the atria and not the ventricle. in addition, this drug has important rate-dependent sodium channel blocking properties. Methods: Currently, there few commercially approved intravenous antiarrhythmic agents for the conversion of atrial fibrillation. intravenously, vernakalant has been demonstrated to be useful in terminating over 50% of recent-onset atrial fibrillation (< 7 days duration) with minimal ventricular proarrhythmic effects. Intravenous vernakalant is not effective in terminating atrial flutter. Oral vernakalant is currently undergoing study and appeats to be effective in suppressing atrial fibrillation recurrences after cardioversion of persistent atrial fibrillation. Results/conclusion: Intravenous vernakalant has the potential to be an important agent in the conversion of atrial fibrillation and oral vernakalant may be a useful drug for the suppression of atrial fibrillation recurrences.

UR - http://www.scopus.com/inward/record.url?scp=44449088060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449088060&partnerID=8YFLogxK

U2 - 10.1517/13543784.17.5.805

DO - 10.1517/13543784.17.5.805

M3 - Review article

C2 - 18447605

AN - SCOPUS:44449088060

VL - 17

SP - 805

EP - 810

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 5

ER -